ISBN-13: 9780323877633 / Angielski / Twarda / 2023
Tentative TOC:
Introduction:
Chapter 1.0 Development and Structure of the Lymphoid System
Chapter 2.0 The Chemistry, Structure, and Function of Immunoglobulins
Chapter 3.0 The Role of the Complement System in Cancer
Chapter 4.0 Cancer as Non-Self
4.1 primary generator of tumor-specific transplantation type antigens
4.2 character of non-self, tumor associated antigens
4.3 immune surveillance - innate immunity
4.4 distinguishing between self and non-self
4.5 toll-like receptors (TLRs); soluble bioactive proteins such as cytokines and C' proteins
4.6 NK cells
Chapter 5.0 The Adaptive Immune Response in Cancer
Chapter 6.0 The Science of Innate Immunity
6.1 critical regulator of human inflammatory disease
6.2 anatomic and physiologic barriers to pathogens - cancer causing viruses
6.3 centrally a limited number of critical receptors
6.4 the character of the inflammatory response
6.5 lack of ability to form memory
6.5 role in activating subsequent adaptive immune response
Chapter 7.0 Immune Surveillance
7.1 history of concept (Ilya Mechnikov 1908 Nobel Prize)
7.2 evidence for immune surveillance today
7.3 cancer in the immunocompromised host
Chapter 8.0 Cancer - Avoiding Immune Detection
8.1 cancer and the presence of immune resistance
8.2 concept for the development of tumor cell tolerance
Chapter 9.0 Active Immunization Against Cancer and Cell-based Therapies
9.1 infusing in-vitro expanded Tumor Infiltrating Lymphocytes (TILs)
9.2 infusing dendritic cells pre-loaded with tumor specific oligopeptide antigens
9.3 B7 co-activating receptor
9.4 vaccines
Chapter 10.0 The Three Major Clinical Components of Cancer Immunotherapy
(modulating cell-mediated immune mechanisms)
10.1 the role of and application of check point blockade
10.2 the role and application of cell-based therapies including CAR-T cell therapies
10.3 antibodies (and vaccines); monoclonal antibodies and novel application of bi- or tri-specifics
Chapter 11.0 The Clinical Application of Immunotherapeutics
11.1 in melanoma cancer
11.2 in breast cancer
11.3 in pancreatic cancer
11.4 in colon and rectum cancer
11.5 in prostate cancer
11.6 in leukemias and hematologic malignancies
11.7 in other malignancies
Chapter 12.0 Cancer Immunotherapy in the Presence of COVID-19
12.1 immune response to coronavirus-2 infection
12.2 CD8+ T cell depression during chronic viral infection and cancer
12.3 checkpoint inhibitors in cancer patients with coronavirus infection
12.4 coronavirus depletion of CD4+ T cells
Czytaj nas na: